VZ PICKED OUT THIS BIO I DON'T KNOW WHY. Hopefully he will fill us in. It's down a full buck and maybe warrants our attention now. For those of you who find Mongo DB too expensive to buy (I'm on that list!-- barely have any) We might watch ZURA this upcomong week. I don't know the story yet but their product is ZB-106. Zura Bio Limited (ZURA) Small Cap Buy Idea- NasdaqCM - NasdaqCM Real Time Price. 6.88+0.13(+1.93%) At close: August 25 04:00PM EDT///
$8.35------$8.60 I think we can get there in Zura. Ultimately $11.25 would be in play. Need to brush up on the story--
Private placement- good idea or dilution? Zura Bio Announces $80 Million Financing and the Licensing of Tibulizumab (ZB-106), a Potential First-in-Class anti-IL-17 and anti-BAFF Dual Antagonist for Autoimmune Diseases April 27, 2023 PDF Version Licensing a potential first-in-class, anti-IL-17 and anti-BAFF dual antagonist In connection with the transaction,Zura Bioannounces pricing of$80 millionprivate placement financing SAN DIEGO--(BUSINESS WIRE)--Apr. 27, 2023--Zura Bio Limited(Nasdaq: “ZURA”) (“Zura” or “Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced the license from Eli Lilly and Company (“Lilly”) of tibulizumab, a potential first-in-class, anti-IL-17 and anti-BAFF dual antagonist. Following the closing, the compound will be known as ZB-106. ZB-106 currently has clinical data from two Phase 1b studies completed in Rheumatoid Arthritis and Sjogren’s Syndrome. The safety profile to date appears to be acceptable, with no new findings relative to known IL-17 and BAFF inhibitors. Chronic toxicology studies have been completed with no adverse drug-related findings. Zura plans to initiate a Phase 2 study for ZB-106 in Systemic Sclerosis in 2024 to be followed by a study in Hidradenitis Suppurativa. Dr. Someit Sidhu, Chief Executive Officer and Director of Zura Bio stated, “We believe tibulizumab is a great complement to our existing multi-asset pipeline. This is the second asset Zura Bio has licensed from Lilly in less than one year. We value their continued partnership and global presence as a leader in the inflammatory disease space and are grateful for the work they have done to progress this asset to its current state. We are excited to advance ZB-106 with the potential to evolve research and impact patients across a number of inflammatory diseases.” Private Placement Financing In connection with the closing of the licensing transaction for ZB-106, Zura has agreed to sell an aggregate of approximately 18.8 million Class A ordinary shares, and pre-funded warrants in lieu of Class A ordinary shares, to certain accredited institutional investors in a private placement financing (the “Offering”). The Offering is expected to result in gross proceeds to Zura of approximately$80 millioncash, before deducting placement agent fees and other offering expenses payable by Zura. In addition, Lilly has agreed to receive up to an aggregate of approximately$4.25 millionin Class A ordinary shares in lieu of a portion of the upfront cash to be paid by Zura as consideration for the licensing transaction for ZB-106. Yikes! So they are licensing ZB-106...From Eli Lilly.... That's' not good.
They got their shares at I think $4.75 and the stk is above $6.00 with no more raise of capital needed for along time./ I'm torn this might work.
My Favorite Republican. New feature***** Growing up one of my idols was Clint Eastwood. I am a big Italian/Western guy and Giorgio Moroder soundtracks-- all those movies and of course this-
TEAM- This is a name I think may be appropriate for my son's account. I can't act on it until I get back to NYC where all my paperwork and acct numbers are. But it looks prime to run. This is going to be another case of me buying something at the HF that's supposed to go into my kid's acct. Which brings us back to SOFI. Anybody like it here @$8.00-?
When you compare two names like CRM to TEAM what do you look for?/ Well if both are down due to market conditions which one has maintained accumulation over distribution? That name is TEAM.
Ted we kind of stumbled into something with eagle. I just spat that out as a cement example but I took a look at the chart and hey we got something. Dowm from $190 and four of the last five bars are green...<------- Eagle Materials Inc. (EXP)-- Add To Buy Idea List****** NYSE - NYSE Delayed Price. 179.60+2.59 (+1.46%) At close: August 25 04:00PM EDT 180.14 +0.54 (+0.30%) After hours: